News & Events – Page 13 – www.brainwork.md

9th May 2018

Start MS drugs early, say new guidelines

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MSGuidelines.jpg 1400 885 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 9th May 2018 13th July 2018

Drug therapy for multiple sclerosis (MS) should be started early, according to updated guidelines from the American Academy of Neurology (AAN), which were presented at…

Peter Stevenson, PhD
0
1

30th April 2018

Solriamfetol improves wakefulness in narcolepsy patients

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Solriamfetol.jpg 1920 1280 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment…

Lutz Achtnichts, MD
0
1

30th April 2018

Huntington’s disease: Antisense drug showing promising results

https://www.brainwork.md/content/uploads/2018/04/Brainwork-HuntingtonsDisease.jpg 4288 3216 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

Results from a Phase I/IIa study of IONIS-HTTRx (RG6042) in Huntington’s disease (HD) were presented in a plenary session at the 2018 annual meeting of the American…

Lutz Achtnichts, MD
0
1

26th April 2018

Promising new migraine treatment presented at AAN 2018

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Erenumab.jpg 5184 3456 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 26th April 2018 13th July 2018

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications…

Lutz Achtnichts, MD
0
2

25th April 2018

A conversation with Dr Jens Kuhle

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 25th April 2018 13th July 2018

This week at AAN in Los Angeles, I had the opportunity to speak with Dr Jens Kuhle about a hot topic, neurofilaments in multiple sclerosis…

Lutz Achtnichts, MD
0
2

6th March 2018

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

https://www.brainwork.md/content/uploads/2018/03/Brainwork-MS.jpg 1600 1067 Julien Ferrari, PharmD, PhD Julien Ferrari, PharmD, PhD https://secure.gravatar.com/avatar/3b67ea7b895dced9b9ed9795a9851ab4?s=96&d=mm&r=g 6th March 2018 13th July 2018

Biogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients. You…

Julien Ferrari, PharmD, PhD
0
2

7th February 2018

A new milestone in acute stroke treatment

https://www.brainwork.md/content/uploads/2018/02/Brainwork-Anewmilestone.jpg 6000 4000 Camilla Norrmén, PhD Camilla Norrmén, PhD https://secure.gravatar.com/avatar/c5fc8d4c102d9ee8db3f93d7f9c6ecd2?s=96&d=mm&r=g 7th February 2018 13th July 2018

Two recent studies have prompted the American Heart Association (AHA) to change their guidelines on early stroke management, extending the window of emergency stroke treatment up…

Camilla Norrmén, PhD
0
0

1st February 2018

From undercooked meat to neuralgic amyotrophy

https://www.brainwork.md/content/uploads/2018/02/MPR425-Brainwork-illustrations-HEV-HERO-image-V00-00-20180201-01.jpg 1920 1080 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 1st February 2018 13th July 2018

We have talked to Dr Paolo Ripellino from the Ospedale Civico di Lugano (EOC), Switzerland, about his research on neurological complications related to hepatitis E…

Michael Furrer, PhD
0
1

15th November 2017

Impressive results for a new vaccine

https://www.brainwork.md/content/uploads/2017/11/Brainwork-ShinglesVaccine-e1510737568680.jpeg 1600 1076 Camilla Norrmén, PhD Camilla Norrmén, PhD https://secure.gravatar.com/avatar/c5fc8d4c102d9ee8db3f93d7f9c6ecd2?s=96&d=mm&r=g 15th November 2017 13th July 2018

Experts are enthusiastic about a new shingles vaccine that received FDA approval last month. Shingrix is significantly more effective than the only currently available shingles…

Camilla Norrmén, PhD
0
0

1st November 2017

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 1st November 2017 13th July 2018

I had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the…

Lutz Achtnichts, MD
0
0

1st November 2017

ECTRIMS-ACTRIMS: A conversation with Dr Patricia Mulero

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 1st November 2017 13th July 2018

At ECTRIMS-ACTRIMS in Paris, France, I had the chance to sit down with Dr Patricia Mulero to discuss FLOODLIGHT: a prospective pilot study that has…

Lutz Achtnichts, MD
0
0

31st October 2017

ECTRIMS-ACTRIMS: A conversation with Dr Tanuja Chitnis

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 31st October 2017 13th July 2018

Children and adolescents living with MS face physical and cognitive disability that can severely limit their ability to perform daily activities, such as attending school.…

Lutz Achtnichts, MD
2
0

Start MS drugs early, say new guidelines​

Solriamfetol improves wakefulness in narcolepsy patients

​Huntington’s disease: Antisense drug showing promising results

​Promising new migraine treatment presented at AAN 2018

A conversation with Dr Jens Kuhle

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

​A new milestone in acute stroke treatment

From undercooked meat to neuralgic amyotrophy

Impressive results for a new vaccine

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

ECTRIMS-ACTRIMS: A conversation with Dr Patricia Mulero

ECTRIMS-ACTRIMS: A conversation with Dr Tanuja Chitnis

Start MS drugs early, say new guidelines

Huntington’s disease: Antisense drug showing promising results

Promising new migraine treatment presented at AAN 2018

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

A new milestone in acute stroke treatment